Oxytocin vs Survodutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Oxytocin
Oxytocin is a natural hormone produced in the hypothalamus, often called the 'love hormone' or 'bonding hormone.' It plays key roles in social bonding, childbirth, lactation, and stress regulation.
Full details →Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Side-by-Side Comparison
| Aspect | Oxytocin | Survodutide |
|---|---|---|
| Mechanism | Binds to oxytocin receptors in the brain and peripheral tissues. Promotes social bonding, reduces anxiety and stress response, and has various peripheral effects on smooth muscle contraction. | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. |
| Typical Dosage | Intranasal: 20-40 IU (international units) for social/anxiolytic effects. Clinical uses (labor induction) require IV administration under medical supervision. | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Intranasal spray for behavioral effects. IV only in clinical settings. Sublingual also possible. Best used situationally rather than continuously. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. |
| Side Effects | Intranasal: headache, nasal irritation, drowsiness. May cause over-attachment or emotional sensitivity. IV (clinical): uterine hyperstimulation, water retention. | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. |
| Best For |
Key Differences
Unique to Oxytocin:
Unique to Survodutide:
Detailed Analysis
Commonalities
Oxytocin and Survodutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Oxytocin for Sleep Quality, Cognitive Performance. Choose Survodutide for Weight Loss, Liver Health.
Ready to Learn More?
Looking for trusted sources?